Cofinimmo Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van Cofinimmo is gedaald met een gemiddeld jaarlijks percentage van -21%, terwijl de winst van de Health Care REITs -industrie jaarlijks daalde met 0.4%. De inkomsten zijn groeide met een gemiddeld percentage van 4.5% per jaar. Het rendement op het eigen vermogen Cofinimmo bedraagt 5.7% en de nettomarge bedraagt 52.9%.
Belangrijke informatie
-20.99%
Groei van de winst
-26.47%
Groei van de winst per aandeel
| Health Care REITs Groei van de industrie | 0.61% |
| Inkomstengroei | 4.46% |
| Rendement op eigen vermogen | 5.67% |
| Nettomarge | 52.91% |
| Volgende winstupdate | 23 Jul 2026 |
Recente prestatie-updates uit het verleden
Recent updates
COFB: Aedifica Merger Progress And Index Exit Will Shape Steady Outlook
Analysts have slightly lifted their fair value estimate for Cofinimmo, increasing the price target from €86.17 to €87.39 as they factor in updated assumptions for the discount rate, revenue trends, profit margin and future P/E. What's in the News Aedifica NV/SA has agreed to acquire the remaining 20.41% stake in Cofinimmo SA for approximately €650 million.COFB: Aedifica Merger Path And Index Removal Will Shape Balanced Outlook
Analysts have kept their Cofinimmo price target steady at €86.17, citing only small adjustments to the discount rate, revenue growth assumptions, and profit margin forecasts. Their long-term view remains broadly unchanged.COFB: Index Removal And 2026 Meeting Will Shape Balanced Risk Profile
Analysts have kept their Cofinimmo price target broadly steady at about €86.17, with the latest update reflecting slightly adjusted assumptions on discount rate, revenue growth and profit margin that leave the implied P/E multiple close to prior levels. What's in the News Cofinimmo SA is recorded as having been removed as an index constituent, which may affect how index funds and ETFs with rules-based mandates treat the stock (Key Developments).COFB: Index Exit And Governance Meeting Will Frame Balanced Risk Reward
Analysts have kept their price target for Cofinimmo broadly steady at €86.17. This reflects only marginal tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in their view of the shares.COFB: Buy Upgrade And Margin Confidence Will Shape Future Risk Reward
Analysts have lifted their price target on Cofinimmo to €86.17 from €86.17. The recent upgrade to Buy supports a slightly more constructive view on its margin profile and long term earnings multiple.COFB: Buy Upgrade And Fair Value View Will Frame Future Risk Reward
Analysts have nudged their price target on Cofinimmo higher to €86.17, reflecting updated assumptions on discount rates, a move to modest revenue growth, a slightly lower profit margin, and a higher forward P/E, alongside a recent upgrade to Buy from a major research house. Analyst Commentary Recent research adjustments give you a clearer view of how the market is framing Cofinimmo at the current price target of €86.17 and the revised assumptions on growth, margins, and P/E.COFB: Buy Upgrade And Refined Assumptions Will Shape Future Risk Reward Balance
Analysts have nudged their fair value estimate for Cofinimmo higher from about €83.72 to around €86.17, citing updated assumptions on discount rates, revenue trends and future P/E, in line with the recent Buy rating upgrade from Kepler Cheuvreux. Analyst Commentary Bullish Takeaways Bullish analysts see the fair value increase from about €83.72 to around €86.17 as support for the recent rating upgrade, suggesting the current share price offers some valuation headroom relative to their assumptions.COFB: Rating Upgrade And Refined Assumptions Will Shape Future Risk Reward Balance
Analysts have modestly adjusted their price targets on Cofinimmo, reflecting slight tweaks to discount rate, revenue growth and profit margin assumptions. Some now see greater upside potential following recent positive research updates and upgrades to Buy.COFB: Rating Upgrade And Refined Assumptions Will Support Fair Value
Analysts have nudged their fair value target for Cofinimmo higher from €81.77 to €83.72, citing updated assumptions around discount rates, profit margins and future P/E, alongside recent positive Street research support. Analyst Commentary Recent Street research has taken a more constructive stance on Cofinimmo, reflected in the higher fair value target of €83.72.COFB: Rating Upgrade And Stable Cash Flows Will Support Fair Value
Analysts have nudged their fair value estimate for Cofinimmo from €81.41 to €81.77, citing a modestly lower discount rate and slightly refined revenue, margin and future P/E assumptions following recent positive Street research. Analyst Commentary Street research has turned more constructive on Cofinimmo, with some analysts moving to a more positive stance and the fair value estimate edging up to €81.77.COFB: Stable Metrics Will Support Fair Value As Risk Perception Slightly Eases
Analysts have trimmed their price target on Cofinimmo slightly to €81.41 from €81.86. This reflects a modestly lower projected future price to earnings multiple and a marginally reduced discount rate in their valuation models.COFB: Stable Metrics Will Support Fair Value Amid Slight Profitability Improvement
Narrative Update on Cofinimmo Analysts have modestly raised their price target on Cofinimmo to EUR 81.86, citing a slightly lower implied discount rate and improved projected profit margins, while growth expectations and valuation multiples remain largely unchanged. Valuation Changes Fair Value: Unchanged at €81.86 per share, indicating a stable intrinsic value estimate.COFB: Financial Metrics Consistency Will Support Stable Fair Value Outlook
Analysts have maintained their fair value estimate for Cofinimmo at €81.86, citing consistent forecasted financial metrics and only minimal updates to underlying assumptions. Valuation Changes Fair Value Estimate remains unchanged at €81.86.COFB: Revenue and Profit Margin Trends Will Shape Fair Value Outlook
Analysts have slightly increased their price target for Cofinimmo from €80.92 to €81.86. They cite improved revenue growth projections and a marginally lower discount rate as key factors behind the adjustment.Healthcare Real Estate Shift Will Yield Lasting Value
Strategic focus on healthcare real estate and divesting non-core areas aims to improve revenue and optimize net margins.Shareholders Of Cofinimmo (EBR:COFB) Must Be Happy With Their 64% Return
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...Opbrengsten en kosten
Hoe Cofinimmo geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 383 | 203 | 11 | 0 |
| 31 Dec 25 | 382 | 213 | 14 | 0 |
| 30 Sep 25 | 390 | 192 | 12 | 0 |
| 30 Jun 25 | 391 | 134 | 13 | 0 |
| 31 Mar 25 | 392 | 111 | 14 | 0 |
| 31 Dec 24 | 392 | 64 | 13 | 0 |
| 30 Sep 24 | 392 | -52 | 12 | 0 |
| 30 Jun 24 | 392 | -41 | 13 | 0 |
| 31 Mar 24 | 391 | -55 | 14 | 0 |
| 31 Dec 23 | 389 | -55 | 14 | 0 |
| 30 Sep 23 | 379 | 49 | 16 | 0 |
| 30 Jun 23 | 379 | 185 | 15 | 0 |
| 31 Mar 23 | 373 | 333 | 14 | 0 |
| 31 Dec 22 | 368 | 483 | 14 | 0 |
| 30 Sep 22 | 367 | 565 | 16 | 0 |
| 30 Jun 22 | 357 | 489 | 14 | 0 |
| 31 Mar 22 | 351 | 382 | 13 | 0 |
| 31 Dec 21 | 343 | 260 | 12 | 0 |
| 30 Sep 21 | 328 | 189 | 15 | 0 |
| 30 Jun 21 | 312 | 155 | 13 | 0 |
| 31 Mar 21 | 276 | 122 | 18 | 0 |
| 31 Dec 20 | 293 | 119 | 10 | 0 |
| 30 Sep 20 | 296 | 170 | 12 | 0 |
| 30 Jun 20 | 266 | 193 | 22 | 0 |
| 31 Mar 20 | 292 | 222 | 9 | 0 |
| 31 Dec 19 | 285 | 205 | 9 | 0 |
| 30 Sep 19 | 241 | 134 | 24 | 0 |
| 30 Jun 19 | 270 | 119 | 8 | 0 |
| 31 Mar 19 | 259 | 105 | 8 | 0 |
| 31 Dec 18 | 263 | 146 | 8 | 0 |
| 30 Sep 18 | 260 | 186 | 8 | 0 |
| 30 Jun 18 | 258 | 170 | 8 | 0 |
| 31 Mar 18 | 264 | 166 | 8 | 0 |
| 31 Dec 17 | 263 | 137 | 8 | 0 |
| 30 Sep 17 | 267 | 121 | 8 | 0 |
| 30 Jun 17 | 267 | 128 | 8 | 0 |
| 31 Mar 17 | 275 | 134 | 8 | 0 |
| 31 Dec 16 | 257 | 97 | 9 | 0 |
| 30 Sep 16 | 253 | 100 | 9 | 0 |
| 30 Jun 16 | 255 | 82 | 9 | 0 |
| 31 Mar 16 | 249 | 110 | 9 | 0 |
| 31 Dec 15 | 255 | 104 | 8 | 0 |
| 30 Sep 15 | 260 | 76 | 8 | 0 |
| 30 Jun 15 | 262 | 66 | 8 | 0 |
Kwaliteitswinsten: COFB heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (52.9%) COFB } zijn hoger dan vorig jaar (28.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van COFB is de afgelopen 5 jaar met 21% per jaar gedaald.
Versnelling van de groei: De winstgroei van COFB over het afgelopen jaar ( 83.2% ) overtreft het 5-jarig gemiddelde ( -21% per jaar).
Winst versus industrie: De winstgroei COFB over het afgelopen jaar ( 83.2% ) overtrof de Health Care REITs -sector 77.8%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 5.7% ) van COFB wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/18 14:54 |
| Aandelenkoers aan het einde van de dag | 2026/06/18 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cofinimmo SA wordt gevolgd door 19 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Celine Huynh | Barclays |
| Kai Klose | Berenberg |
| Robert Jones | BNP Paribas |